This cohort of patients more frequently received some DPP4 inhibitor in addition to metformin, which are recommended in first and second line in different clinical scenarios; however, current evidence suggests that the best combination in patients who also have CKD is metformin plus an SGLT2i [9], a therapy that only 17% of patients received; or metformin plus a GLP1a, which was observed in only 5.2% of cases, as these treatments have shown a benefit on renal function and reduction of proteinuria [12, 29–33]. Here, DPP4 is linked to chronic kidney disease.